Floatz logo

Pembrolizumab

Colorectal Adenocarcinoma

Salubris Biotherapeutics Incmonoclonal_antibodyPhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
73/ 100

Competitive context

66 Active assets in the Colorectal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Trifluridine
Centre Hospitalier Universitaire Dijon
Phase 3BB
Regorafenib
City of Hope Medical Center
Phase 2BB
Balstilimab
City of Hope Medical Center
Phase 2BB
Botensilimab
City of Hope Medical Center
Phase 2BB
Eloxatin
Pfizer
Phase 3BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →